Global Protein Detection Quantification Market - 2020-2027
発行: DataM Intelligence
Detection and subsequent quantification of proteins is a vital step in the understanding of post-translational modifications. It assists in the understanding of the functions of complex networks of peptide for use in medicine and cell biology. Increased demand for quantification of protein in laboratories that are engaged with various activities. The activities in these laboratories range from drug dosing and clinical diagnostic testing to protein characterization and are likely to influence the industrial growth in the years to come. Factors such as these are likely to propel expansion of the global protein detection and quantification market.
Furthermore, various candidate biomarkers developed through proteomics and genomics research have the potential to serve as predictive indexes for producing safer and more effective drugs. In the discovery stage, differential proteomic analysis with the help of mass spectrometry enables the recognition of candidates which are linked with a specific mechanism relevant to disease progression and affected by drug treatment.
Incorporation of informative biomarkers as predictive tools in clinical trials is increasingly viewed for not only enabling smarter decisions but also as a resource investment for the development of potential diagnostics. The aforementioned fact is anticipated to drive the clinical diagnostics segment with the fastest rate
Selection of an appropriate technology out of a large number of available methods of quantitation for the kind of protein to be detected and its concentration in the sample remains an important step in biotechnology protocols.
The market is driven is the rising number of traumatic injuries. The market growth is also majorly driven by the increasing need to understand chronic diseases at a molecular level and develop therapeutic solutions is expected to encourage these organizations to fund research and development programs. In addition, Public Health Genomics at the National Cancer Institute (NCI) promotes the integration of personalized medicine and genomics into public health cancer research in an attempt to reduce the burden of cancer across the globe.
Governments are encouraging the research activities by raising funds in the field of proteomics industry and thus the protein detection and quantification market is anticipated to grow at a significant pace in the coming years. The presence of organizations such as the Human Proteome Organization, National Cancer Institute (NCI), and Genomic Health Inc. promotes funding to support R&D and product development exercises pertaining to the field of proteomics.
Furthermore, proteomic studies carried out on for finding the mechanism of physical and chemical degradation pathways of biologics are anticipated to propel progress. In addition to advancements, the development of next-generation techniques for the protein concentration estimation is expected to drive the market with potential avenues.
In addition, various candidate biomarkers developed through proteomics and genomics research have the potential to serve as predictive indexes for producing safer and more effective drugs. In the discovery stage, differential proteomic analysis with the help of mass spectrometry enables the recognition of candidates which are linked with a specific mechanism relevant to disease progression and affected by drug treatment.
Although technological advancements continue to take place for simplification protein estimation, high cost of technology and assays are anticipated to restrict the usage of these assays and technologies under certain circumstances. For instance, Mass Spectroscopy (MS) which is often used for functional proteomics is considered expensive and slow by researchers. In targeted MS, custom antibodies are required for each target to perform immunoaffinity enrichment of peptides. This process is observed to be expensive as well as lengthy.
Increasing need to comprehend various chronic diseases at a molecular level and then come up with therapeutic solutions is estimated to support these organizations to invest in research and development programs. Besides, Public Health Genomics at the National Cancer Institute (NCI) boosts incorporation of genomics and personalized medicine into research of public health cancer in an effort to diminish the burden of cancer all over the world.
The COVID-19 outbreak has negatively affected the growth of the market. The centers are closed and the laboratories are busy in the COVID-19 test which will hamper the market growth in the forecast period.
The global protein detection quantification market is segmented based on technology by colorimetric assays, immunological methods, chromatography, mass spectrometry, spectroscopy instruments, others. The colorimetric assays segment held the largest market share due to its convenience rate and wide availability of the reagents for its implementation. Colorimetric assays are based on the binding of a specific dye to the rhamnolipid.
Colorimetric assays help to distinguish a particular enzyme from another, to quantitate catalytic activity, as well as inhibition of this activity, to generate proliferative and toxicity profiles, and even to determine the concentration of proteins in solution. They are a simple and convenient way to visualize biological processes.
In colorimetric assays, the substrate is converted by the enzyme into a soluble, colored reaction product. This allows precise determination of the enzyme activity by optical density such as peroxidase activity is measured by the reduction of the substrate in the presence of hydrogen peroxide, producing a soluble chromogen that is measured with a spectrophotometer. These colorimetric assay methods are often used for microtiter plate-based ELISAs in combination with an automated spectrophotometer.
The testing of protein concentration was done using citrate buffer with tetra bromophenol blue and the change of color observed was from yellow to blue. These are well known colorimetric assays commonly used in urine analysis. The different chemicals and enzymes were spotted at the last step of the device fabrication and left to dry in the detection zones. Similar glucose and protein tests were tried on devices patterned with different methods
Kinases and phosphatases mediate a variety of cellular processes like metabolism, gene transcription and translation, protein-protein interactions, and apoptosis, through protein phosphorylation and dephosphorylation. For this reason, many different technologies, including various colorimetric assays, exist to detect these enzymes and their activity. This factor will drive the growth of the market in the forecast period.
The chromatography segment is expected to have positive market growth due to the enable researchers for detection and monitoring changes in the biomarker concentration, down to a femtogram level, with scope to increase the limit of detection with further fine-tuning down the line.
Chromatography is the most widely used separation technique in chemical laboratories, where it is used in analysis, isolation and purification, and it is commonly used in the chemical process industry as a component of small and large-scale production. In terms of scale, at one extreme minute quantities of less than a nanogram are separated and identified during analysis, while at the other, hundreds of kilograms of material per hour are processed into refined products. It is the versatility of chromatography in its many variants that is behind its ubiquitous status in separation science, coupled with simplicity of approach and a reasonably well-developed framework in which the different chromatographic techniques operate.
Chromatography is essentially a physical method of separation in which the components of a mixture are separated by their distribution between two phases. This factor will drive the growth of the market in the forecast period.
Further, the market is also classified based on application as drug discovery and development, clinical diagnosis, others. The drug discovery and development segment is held the largest market share. The drug discovery and development is the processes involved, and how pharmaceutical chemists perform their chemistry using batch and flow chemistry systems. The process of bringing a new medicine to market is extremely challenging, costing an average of $2.6B and taking up to 12 years. It is therefore important for pharmaceutical companies to optimize the drug discovery and development process, to maximize the lifetime of the medicine before patents expire.
Drug discovery typically begins with target identification is selecting a biochemical mechanism involved in a disease condition. Up to 10,000 drug candidates are then put through a rigorous screening process to establish their interaction with the drug target. Once initial "hits" (drugs with activity against the target) are identified, a focused library of similar compounds will be synthesized to optimize interactions with the drug target; this is the process of library synthesis. This factor will drive the growth of the market in the forecast period.
The clinical diagnosis segment is expected to have positive market growth due to the growing incidence of infectious and chronic diseases, and increasing adoption of the automated platform. Infectious and chronic diseases are considered the leading causes of death, worldwide. According to the World Health Organization, lower respiratory infections remained the most deadly communicable diseases that caused 3.0 million deaths worldwide in 2016.
People with infectious diseases and chronic conditions are the most frequent users of healthcare and account for the majority of hospital admissions and clinical diagnostics done. These diseases account for the vast majority of healthcare spending. The average healthcare coverage costs for people with a chronic condition is five times higher than for those without such a condition.
The clinical diagnostics have been proved to be beneficial in chronic disease conditions since they are extremely valuable for disease prevention, detection, and management by influencing to make the correct clinical decision-making. This factor will drive the growth of the market in the forecast period.
By region, the global protein detection quantification market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global protein detection quantification market and is expected to grow at the highest CAGR during the forecast period. The region is estimated to be driven by the US mainly due to the presence of leading market players in the country together with a well-established healthcare framework in the US. A combination of factors such as developed infrastructure, an increase in R&D investment, and growing cases of various diseases in the region are the factors attributed to the market growth in the U.S.
Asia Pacific is likely to come up as a rapidly growing region owing to rapid development of countries like India and China. Augmented investment for research and development activities together with rising cases of several diseases in the area is likely to boost the protein detection and quantification market in the region.
Continuous efforts of government and top-notch private firms in novel drug discovery and development are expected to impact proteomics growth in this country. For instance, recently researchers at The Scripps Research Institute (TSRI) have developed a new toolkit that enables them to discover and reveal the new functional characteristics of peptide biomolecules. They have developed new probes based on activity-based peptide -profiling (ABPP) for the detection of potential drug targets. This factor will drive the growth of the market in the region.
The global protein detection quantification market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition Merck & Co., Inc., Danaher, RayBiotech, Inc., Inanovate, Shimadzu Corporation, PerkinElmer Inc, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, and GE Healthcare are the leading market players with significant market share. The major players are using product development, novel product launches, market expansion, and product diversification strategies for holding their position in the market.
The companies are entering into collaborations, mergers, strategic partnerships, and acquisitions to expand their presence and meet the rising demand for the protein detection quantification across the globe. For instance,
*The global protein detection quantification market report will provide access to approximately 70 market data tables, 69 figures, and 250 pages.